FLGT vs. VCYT, HTFL, CELC, LFST, ADUS, PGNY, ARDT, NHC, AVAH, and PACS
Should you be buying Fulgent Genetics stock or one of its competitors? The main competitors of Fulgent Genetics include Veracyte (VCYT), Heartflow (HTFL), Celcuity (CELC), LifeStance Health Group (LFST), Addus HomeCare (ADUS), Progyny (PGNY), Ardent Health (ARDT), National HealthCare (NHC), Aveanna Healthcare (AVAH), and PACS Group (PACS). These companies are all part of the "healthcare" industry.
Fulgent Genetics vs. Its Competitors
Veracyte (NASDAQ:VCYT) and Fulgent Genetics (NASDAQ:FLGT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.
Veracyte has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.
Veracyte has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.
48.1% of Fulgent Genetics shares are owned by institutional investors. 1.4% of Veracyte shares are owned by insiders. Comparatively, 31.8% of Fulgent Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Veracyte currently has a consensus price target of $40.90, indicating a potential upside of 32.45%. Fulgent Genetics has a consensus price target of $25.33, indicating a potential upside of 15.78%. Given Veracyte's stronger consensus rating and higher probable upside, analysts clearly believe Veracyte is more favorable than Fulgent Genetics.
In the previous week, Veracyte had 5 more articles in the media than Fulgent Genetics. MarketBeat recorded 11 mentions for Veracyte and 6 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.80 beat Veracyte's score of 1.02 indicating that Fulgent Genetics is being referred to more favorably in the news media.
Veracyte has a net margin of 5.50% compared to Fulgent Genetics' net margin of -16.83%. Veracyte's return on equity of 6.07% beat Fulgent Genetics' return on equity.
Summary
Veracyte beats Fulgent Genetics on 13 of the 16 factors compared between the two stocks.
Get Fulgent Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulgent Genetics Competitors List
Related Companies and Tools
This page (NASDAQ:FLGT) was last updated on 9/13/2025 by MarketBeat.com Staff
